--- title: "Morning Trend | TOUYUN BIOTECH continues to decline with increasing volume, will the short-term extreme intensify?" type: "News" locale: "en" url: "https://longbridge.com/en/news/273487800.md" description: "On January 23, TOUYUN BIOTECH (1332.HK) encountered a significant drop during the trading session, with a substantial increase in trading volume throughout the day, leading to a decline in risk appetite to a recent low. There is a strong risk-averse sentiment among investors, making it difficult for the main players in the market to show clear signs of replenishment. The trading is dominated by a wait-and-see attitude, and the funds attempting to buy on the left side are unable to reverse the overall pressure. From an industry perspective, favorable news for the biotechnology sector has been scarce since the beginning of the year, with continuous outflows of funds from the main line of the sector. Companies with high R&D investments frequently report performance losses, leading to a cooling of market enthusiasm. Ongoing tightening of overseas regulations and delays in drug review and approval processes have resulted in a lack of marginal improvement momentum for the overall sector. TOUYUN BIOTECH's stock price has consecutively fallen below important moving averages in recent trading days, with the MACD falling below the zero axis, and all short-term moving averages have broken down, indicating a continuous release of short-term bearish energy and extremely weak rebound momentum. Technically, the key support level is around 0.20; if it is breached again, bearish pressure may further intensify. Although trading volume has increased, there is no clear sign of a stop-loss rebound, with low participation from the main players and a lack of confidence. In terms of operational strategy, it is not recommended to blindly chase rebounds; before there is a clear return of funds and improvement in fundamentals, special attention should be paid to whether the trading volume can gradually converge and any minor sector movements. Before signs of replenishment from main funds or sudden favorable news in the industry appear, short-term elasticity is limited, and ordinary investors should focus on risk prevention to avoid chasing highs and cutting losses" datetime: "2026-01-26T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273487800.md) - [en](https://longbridge.com/en/news/273487800.md) - [zh-HK](https://longbridge.com/zh-HK/news/273487800.md) --- # Morning Trend | TOUYUN BIOTECH continues to decline with increasing volume, will the short-term extreme intensify? On January 23, TOUYUN BIOTECH (1332.HK) encountered a significant drop during the trading session, with trading volume increasing throughout the day, and risk appetite in the market falling to a recent low. There is a strong risk aversion sentiment among investors, making it difficult for the main players in the market to show clear signs of replenishment. A wait-and-see attitude dominates trading, and funds attempting to buy on the left side are unable to reverse the overall pressure. From an industry perspective, favorable news for the biotechnology sector has been scarce since the beginning of the year, with mainline funds continuously flowing out of the sector. Companies with high R&D investments frequently report expected losses, leading to a cooling of market enthusiasm. Ongoing tightening of overseas regulations and delays in drug review and approval processes have resulted in a lack of marginal improvement momentum for the overall sector. TOUYUN BIOTECH's stock price has consecutively fallen below important moving averages in recent trading days, with the MACD falling below the zero axis, and all short-term moving averages breaking down, indicating that short-term bearish energy continues to be released, with very weak rebound momentum. Technically, the key support level is in the 0.20 area; if it is breached again, bearish pressure may further intensify. Although trading volume has increased, there are no clear signs of a stop-loss rebound, with low participation from main players and a lack of confidence. In terms of operational strategy, it is not recommended to blindly chase rebounds; before there are clear signs of capital inflow and fundamental improvement, special attention should be paid to whether trading volume can gradually converge and any minor sector movements. Before signs of replenishment from main funds or unexpected favorable news in the industry appear, short-term elasticity is limited, and ordinary investors should focus on risk prevention to avoid chasing highs and cutting losses ### Related Stocks - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [01332.HK](https://longbridge.com/en/quote/01332.HK.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) ## Related News & Research - [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md) - [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md) - [05:22 ETEnergenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026](https://longbridge.com/en/news/284533464.md) - [FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | FDXTF Stock News](https://longbridge.com/en/news/284651899.md) - [CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026](https://longbridge.com/en/news/284213122.md)